Dutch firm Nexus Technology enters the market for laptop accessories with a new patented liquid cooling solution. The TDD-9000 is a soft black velvet blanket with inside a gel-like liquid. The patented liquid has unique heat dissipating characteristics and works completely passive and noiseless.

"When you put the laptop cooling pad on your lap you will feel your lap turn colder within 10 seconds," says Michael van der Jagt, CEO of Nexus Technology. "The Taiwanese testing institute SGS Taiwan has done independent tests that support these claims.

A new study has shown that the effectiveness of the Komodo Dragon bite is a combination of highly specialized serrated teeth and venom and the authors say this dismisses the widely accepted theory that prey die from septicemia caused by toxic bacteria living in the dragon's mouth.

Using sophisticated medical imaging techniques, an international team led by Dr Bryan Fry from the University of Melbourne have revealed that the Komodo Dragon (Varanus komodoensis) has the most complex venom glands yet described for any reptile, and that its close extinct relative Megalania was the largest venomous animal to have lived.

A team of Vanderbilt University Medical Center investigators say they have cracked one of clinical medicine's enduring mysteries – namely, why the once-effective tuberculosis vaccine no longer prevents the bacterial lung infection that kills more than 1.7 million people worldwide each year. 

The solution could lead to an improved TB vaccine and also may offer a novel platform for vaccines against other pathogens. 

The current TB vaccine, known as BCG (bacille Calmette-Guérin), has been around since the 1920s. It was made by weakening (attenuating) a strain of bacteria that causes tuberculosis in cows and that genetically is 98 percent identical to the human TB germ. 

The secret to any good recipe is knowing how things happen in a system and the recipe for diseases is no different.  Many diseases have crucial proteins which change the dynamics of cells from benign to deadly. New findings from an international collaboration involving McGill University, the Research Institute of the McGill University Health Centre (MUHC) and the Human Proteome Organisation (HUPO) just made identifying these changes one step easier. Their findings published in Nature Methods, show how to improve protein analysis to tease out relevant potential disease-causing molecules.

Since April 15 and 17, 2009, when the first two cases of novel influenza A (H1N1) infection were identified from two southern California counties, novel influenza A (H1N1) cases have been documented throughout the world, with most cases occurring in the United States and Mexico.

In the United States, early reports of illnesses associated with novel influenza A (H1N1) infection indicated the disease might be similar in severity to seasonal influenza, with the majority of patients not requiring hospitalization and only rare deaths reported, generally in persons with underlying medical conditions.

LONDON, May 19 /PRNewswire/ --

- Study Results Demonstrate Patients Adhere to Treatment Regimens With EVISTA(R)

To view a Vodcast of Professor Peyman Hadji presenting the data click the following link: http://62.193.238.61/blueprinttv/expert/Expert-Opinion.html

To view a Vodcast of a Patient's Perspective click the following link: http://62.193.238.61/blueprinttv/expert/The-Patient-Perspetive.html

LONDON, May 19 /PRNewswire/ --

Data presented today at the 8th European Congress on Menopause (EMAS) demonstrated that the majority of osteoporosis patients treated with EVISTA(R) (raloxifene) stay on therapy for the first two years.

LONDON, May 19 /PRNewswire/ --

- Study Results Demonstrate Patients Continue to Adhere to Treatment With Raloxifene

To view a Vodcast of Professor Peyman Hadji presenting the data click here: http://62.193.238.61/blueprinttv/expert/Expert-Opinion.html

To view a Vodcast of a Patient's Perspective click here:

http://62.193.238.61/blueprinttv/expert/The-Patient-Perspetive.html

WARRENDALE, Pennsylvania, May 18 /PRNewswire/ --

MEDRAD Interventional(TM)/Possis(R) today announced that it has reached key milestones in bringing the Paccocath(R) Technology closer to market as an option for the over 14 million patients in the United States and Europe who suffer from Peripheral Arterial Disease (PAD). These milestones include the selection of physician investigators for U.S. clinical trials and the completion of a new state-of-the-art manufacturing facility.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )

CAMBRIDGE, Massachusetts, May 18 /PRNewswire/ --

A potential new player in Cameroon's mobile market and regulatory pressure to cut prices will help to more than double the country's mobile penetration by 2014, according to a new report from Pyramid Research (www.pyr.com), the telecom research arm of the Light Reading Communications Network (www.lightreading.com).

BARCELONA, Spain, May 18 /PRNewswire/ --

CeloNova BioSciences, Inc., today announced that it will showcase the technology behind the CATANIA(TM) Coronary Stent System featuring a NanoThin Polyzene(R)-F surface treatment as part of the Company's participation in the EuroPCR conference May 19-22.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090518/CL18788) (Photo: http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-b)